Namenda XR (Alzheimer’s Disease)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer’s Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Strategic Competitor Assessment 40
6 Opportunity and Unmet Need 43
6.1 Unmet Needs Overview 43
6.1.1 Public Awareness 45
6.1.2 Specialized Institutions at Local Levels 46
6.1.3 Screening and Diagnosis 46
6.1.4 Early Intervention 47
6.1.5 Improved Clinical Trial Design 48
6.1.6 Effective Therapy 49
6.1.7 Behavioral Treatments 50
6.2 Gap Analysis 50
6.2.1 Disease Prevention 51
6.2.2 Diagnosis from Biomarkers 52
6.2.3 Behavioral Therapies 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Early-Stage Pipeline Assessment 54
7.3 AD Pipeline by Mechanism of Action 56
7.4 Enzymatic Processing 57
7.5 Immunization 58
7.6 Anti-Aggregation 58
7.7 “Me-Too” 59
7.8 Novel Therapeutic Approaches 60
7.9 Technology Trends Analytic Framework 61
7.10 Promising Drugs in Clinical Development 62
8 Namenda XR 64
8.1 Overview 64
8.2 Efficacy 64
8.3 Safety 65
8.3.1 Dosing and Formulation 65
8.3.2 Potential Clinical Positioning 65
8.3.3 Potential Commercial Positioning 65
8.3.4 Pricing and Reimbursement 66
8.4 SWOT Analysis 66
8.5 Forecast 66
9 Appendix 67
9.1 Bibliography 67
9.2 Abbreviations 85
9.3 Methodology 92
9.4 Forecasting Methodology 92
9.4.1 Diagnosed AD patients 93
9.4.2 Percent Drug-treated Patients 94
9.4.3 General Pricing Assumptions 94
9.4.4 Generic Erosion 96
9.4.5 Pricing of Pipeline Agents 96
9.4.6 Alternate Scenarios 96
9.5 Physicians and Specialists Included in this Study 97
9.6 About the Authors 98
9.6.1 Author 98
9.6.2 Global Head of Healthcare 99
9.7 About GlobalData 100
9.8 Disclaimer 100